Vitamin D in Multiple Sclerosis

Brief Description Of Study

The purpose of this study is to determine if giving a higher dose of vitamin D3 results in lower risk of MS attacks or worsening.

Clinical Study Identifier: TX257

Detailed Study Description

Eligible participants include relapsing remitting multiple sclerosis patients that are willing to start daily administration of glatiramer acetate (also known as Copaxone) for the study. Participants will also take a daily high or low dose of vitamin D3 as an add-on therapy, Patients that have already started copaxone may also be eligible to participate if they have not been on copaxone for more than 90 days. Participants will complete study related and safety assessments over a two year period. Both the Copaxone and Vitamin D will be provided to particpants free of charge through the study. * Please note, patients must also be able to walk 500 meters (1640 feet) without rest or assistance.

Contact research investigator to learn more about this study by filling out the form below.

To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: Vitamin D in Multiple Sclerosis
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.